drugset / Trial / NCT03489395

A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation

NCT03489395

NaSingle-groupOpen-labelTreatment

Summary

Isolated reports have indicated that complete Left Atrial or Left Atrial Appendage thrombus resolution may be achieved also with use of oral Factor Xa inhibitors, which have demonstrated the same efficacy but a better safety profile compared to warfarin. The aim of this open-label pilot study is to investigate the percentage of Left Atrial /Left Atrial Appendage thrombus resolution with edoxaban therapy in patients with non-valvular atrial fibrillation. The subordinated aim is the design a larger and longer study to compare edoxaban and warfarin in the same patient population. With the exception of few case reports, there are no data in the same patient population referred to antithrombotic treatments other than vitamin K antagonists.

Timeline

Start
2018-01-30
Primary completion
2020-12-31
Completion
2021-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 30 mg
Subject Edoxaban Small molecule 60 mg

Indications